DPP4 and type 2 diabetes mellitus: Additional systematic reviews encompassing both randomized and non-randomized studies have similarly indicated that incretin therapy, that is, DPP-4 inhibitors, does not seem to be correlated with an elevated risk of pancreatitis in individuals with T2D (Li et al., 2014).